in new york, su keenan, bloomber g. rishad: one of the biggest deals and pharmaceutical history could be signed off today. the boards are close to announcing their megamerger which could be worth north of $150 billion. what do we actually know? this is going to see the maker of-- david: this is going to see the maker of viagra merge with the maker of -- 11.5 shares are being offered for each. that was before the deal was made public. they have been struggling with generic drugs. if we have a look at the share price of allergan, it has done well for the past months. deal hast pfizer, a pull-backa little in the share price. ian reid will head the new company. rishad: we are getting a few of the nuts and bolts. we've had a wave of consolidation in this industry. not all of it is for obvious logic. some of it is to impress the irs there in this state? juliett: this deal is trying to be tax advantageous. essentially, this merged company will take benefits of lower corporate tax rates in europe and be structured as a reverse merger.